Pantoprazole

證據等級: L5

預測適應症: 6 個

Pantoprazole: From Acid-Suppression Therapy (Original Indication Data Unavailable) to Active Peptic Ulcer Disease

One-Sentence Summary

Pantoprazole is a proton pump inhibitor (PPI); no formal original-indication text is available in this evidence pack because the drug is not currently marketed in this jurisdiction. The TxGNN model's top prediction is Active Peptic Ulcer Disease, supported by 3 clinical trials and 19 publications — though it should be noted this largely reflects pantoprazole's already-established pharmacological class effect (acid suppression for peptic ulcer disease) rather than a novel repurposing signal.

Quick Overview

Item	Content
Original Indication	Not available (no approved license/indication text on file; drug not marketed)
Predicted New Indication	Active Peptic Ulcer Disease
TxGNN Prediction Score	99.69%
Evidence Level	L1
New Zealand Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, pantoprazole is a member of the proton pump inhibitor (PPI) class, which binds irreversibly to the gastric parietal cell H+/K+-ATPase to reduce gastric acid secretion. This is the well-established mechanism underlying PPI efficacy across acid-related gastrointestinal disorders.

Active peptic ulcer disease is a classic acid-related condition, and acid suppression via H+/K+-ATPase inhibition is the standard pharmacological rationale for ulcer healing and H. pylori eradication regimens. Multiple completed trials in this evidence pack (including a Phase 3 active-controlled RCT against ilaprazole) directly test pantoprazole in gastric/duodenal ulcer populations.

Important caveat: the model's own rationale for this candidate explicitly notes that acid suppression for peptic ulcer disease is pantoprazole's already-approved use, not a newly discovered indication. The high score and strong evidence level (L1) here should therefore be read as a validation of known pharmacology rather than a genuine repurposing opportunity, and any Go/Guardrail decision should be framed accordingly.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02197039	N/A	Completed	316	Prospective study identifying risk factors for poor stigmata fading/early rebleeding after endoscopic hemostasis plus high-dose PPI infusion, to guide selection for second-look endoscopy
NCT00930670	Phase 4	Completed	320	Evaluated the effect of various PPIs (including pantoprazole) and statins on clopidogrel antiplatelet activity in patients undergoing PCI with dual antiplatelet therapy
NCT02084420	Phase 3	Completed	323	Multicenter, randomized, double-blind, active-controlled trial comparing ilaprazole vs. pantoprazole triple therapy for 7-day H. pylori eradication in H. pylori-positive gastric and/or duodenal ulcer patients

Literature Evidence

PMID	Year	Type	Journal	Key Findings
18824852	2008	RCT	Digestion	Prospective RCT comparing intermittent vs. continuous pantoprazole infusion for prevention of peptic ulcer rebleeding after endoscopic hemostasis
12752349	2003	RCT	Aliment Pharmacol Ther	Compared efficacy of three pantoprazole-based triple therapy regimens for H. pylori eradication and gastric ulcer healing
15244210	2003	Cohort	Hepato-gastroenterology	Compared efficacy of lansoprazole vs. pantoprazole in treatment of active duodenal ulcer and H. pylori eradication
38384180	2024	Cohort	Gut and Liver	Multicenter, randomized, active-controlled study validating acid suppressant therapy (PPI-class comparator) for ESD-induced artificial ulcer healing
19938880	2009	Review	Clinical Drug Investigation	Comprehensive review of pantoprazole pharmacology; notes no clinically significant drug-drug interactions identified across numerous interaction studies
9017763	1997	Review	Pharmacotherapy	Review of PPI mechanism (H+/K+-ATPase inhibition) and comparative superiority over H2-receptor antagonists in acid-related disease control
38345252	2024	Review	Am J Gastroenterology	Systematic review/network meta-analysis comparing P-CAB vs. PPI efficacy and safety in healing Grade C/D esophagitis
10983736	2000	Review	Drugs	Review of esomeprazole, comparing intragastric pH control against omeprazole, lansoprazole, and pantoprazole in GORD trials
11693467	2001	Review	Drugs	Update on lansoprazole's role in acid-related disorder management, including peptic ulcer disease and H. pylori eradication regimens
38652367	2024	Preclinical	Inflammopharmacology	Rat model study of combined pantoprazole + mesenchymal stem cell therapy on experimentally induced gastric ulcer, examining oxidative stress, inflammation, and apoptosis pathways

New Zealand Market Information

Pantoprazole currently has no registered authorizations on file — market status is Not Marketed, with 0 total licenses recorded in this evidence pack.

Safety Considerations

Please refer to the package insert for safety information. (No TFDA warnings, contraindications, or drug-drug interaction data were retrievable at the time of this evidence pack's compilation.)

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Evidence level L1 is supported by a directly relevant Phase 3 active-controlled RCT and multiple RCT/cohort studies, but this strength primarily confirms pantoprazole's already-established PPI-class efficacy in peptic ulcer disease rather than revealing a novel repurposing opportunity — this distinction must be explicit in any downstream use of this candidate. Separately, a Blocking-severity data gap (missing TFDA package-insert warnings/contraindications) currently prevents completion of the S1 safety initial screen.

To proceed, the following is needed:

TFDA package insert (warnings, contraindications) — Blocking gap, required before S1 safety screening can complete
Confirmed mechanism-of-action documentation from DrugBank — needed for a rigorous, non-generic mechanistic-relevance analysis
Explicit reviewer note that "Active Peptic Ulcer Disease" reflects known PPI pharmacology, not a novel signal, before this candidate is used to justify new-indication claims
Market/licensing status update if commercial launch in this jurisdiction is planned, since 0 authorizations currently exist
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.